// App-Quantinova.ai

4501 : Effect of cabozantinib on immunosuppressive subsets in metastatic urothelial carcinoma.

Researchers

Presenter

  • Andrea Borghese Apolo

Principal Investigators

  • Yusuke Tomita

  • Seth M. Steinberg

  • James L. Gulley

  • Jeffrey Schlom

  • Donald P Bottaro

  • Jane B. Trepel

  • Min-Jung Lee

  • Sunmin Lee

  • Ari Frosch

Medical Centers

  • Laboratory of Tumor Immunology and Biology, National Cancer Institute at the National Institutes of Health, Bethesda, MD

  • Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MDBiostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, MDUrologic Oncology Branch, National Cancer Institute, Bethesda, MD

  • National Institute of Health, Bethesda, MD

  • Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD

  • National Human Genome Research Institute, National Institutes of Health, Bethesda, MD

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Advanced Urothelial Carcinoma

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 14

  • Cluster of Differentiation 4

  • Cluster of Differentiation 40

  • Programmed cell death protein 1

  • Regulatory T cells

Drug/Treatment

  • Cabozantinib

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved